NWNan Wu

Nan Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nan Wu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Fangxuan Li

    Cancer Prevention Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    1 shared publication
  • Jinpu Yu

    Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, China.

    1 shared publication
  • Junsheng Mu

    Beijing University of Posts and Telecommunications

    1 shared publication
  • Juntian Liu

    Department of Cancer Prevention Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    1 shared publication
  • Lijuan Li

    Cancer Prevention Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    1 shared publication
  • Lijuan Wei

    Cancer Prevention Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    1 shared publication

Latest Publications

  • Open Access

    RIS-Aided OTFS: A Novel ISAC Scheme for Achieving Real-Time Communication and Sensing

    by Zhongjie Li, Weijie Yuan, Zexuan Jing, Junsheng Mu, Nan Wu, Zhiyun Lin

    In this paper, we study uplink transmission for reconfigurable intelligent surfaces (RIS)-aided orthogonal time frequency space (OTFS) systems to achieve real-time communications and sensing in high-mobility scenarios, which is the urgent requirement for various future networks like Internet of Things (IoT) and Metaverse. To this end, we first propose an efficient and reliable transmission scheme which utilizes the delay-Doppler information in OTFS to facilitate the configuration of RIS. Specifically, the proposed scheme exploits the estimated delay and Doppler shifts of the cascaded channel to sense the user, and the sensing parameters are then used for RIS passive beamforming. It is noteworthy that we estimate the channel state information (CSI) by employing only one OTFS frame and configure the RIS based on the predicted channel parameters, leading to substantially reduced channel training overhead and more real-time RIS configuration. To obtain the essential information for channel information sensing, we then propose a low-complexity algorithm which determines the Doppler and delay shifts of the channel between the user and RIS based on the mapping relationship of the delay-Doppler pairs. With the delay-Doppler information in hand, a user tracking scheme relying on extended Kalman filter (EKF) are then presented to track the user and obtain the spatial angle information. By making use of the channel parameters acquired at the base station (BS), the RIS reflection vector is designed to maximize the achievable rate. The results obtained from the simulation experiments affirm the efficacy of the proposed scheme, thereby confirming its capability to attain efficient communications and sensing under high Doppler channels.


  • Perspectives on the role of breast cancer susceptibility gene in breast cancer

    by Nan Wu, Lijuan Wei, Lijuan Li, Fangxuan Li, Jinpu Yu, Juntian Liu

    Purpose Breast cancer susceptibility gene 1/2 can repair damaged DNA through homologous recombination. Besides, the local immune microenvironment of breast cancer is closely linked to the prognosis of patients. But the relationship of breast cancer susceptibility gene 1/2 expression and local immunosuppressive microenvironment in breast cancer is not clear. The aim of this study was to discuss the correlation between them. Methods The fresh primary breast tumors and paired normal tissues of 156 cases of breast cancer patients as well as peripheral blood of 156 cases among them in Tianjin Medical University Cancer Institute and Hospital from January 2014 to October 2018 were collected. The association between breast cancer susceptibility gene 1/2 germline mutation and immune status of microenvironment in situ was analyzed. Results The results indicated that the germline mutation of breast cancer susceptibility gene 1/2 was inconsistent with the breast cancer susceptibility gene 1/2 protein expression, and the proportion of immune cells in patients with negative expression of breast cancer susceptibility gene 1/2 protein was higher than patients with positive expression of breast cancer susceptibility gene 1/2 protein (p < 0.05). And the expression of programmed cell death protein 1, cytotoxic T-Lymphocyte Antigen 4, programmed death ligand-1 of CD3+ T cells in patients with negative expression of breast cancer susceptibility gene 1/2 protein was higher than patients with positive expression of breast cancer susceptibility gene 1/2 protein (p < 0.05). The breast cancer susceptibility gene 1 protein expression was significantly correlated with family history of breast cancer patients (p = 0.006), local lymph node metastases (p = 0.001), and TNM staging (p ≤ 0.001). The breast cancer susceptibility gene 2 protein expression was significantly related to local lymph node metastases (p ≤ 0.001), III stage rate(p = 0.003) and molecular subtyping (p ≤ 0.001). Besides, the 5 years disease free survival was worse for G1 group and pathological III stage patients than other groups and other TNM stage patients. Conclusion In short, the immune therapy may be a potential therapy method for breast cancer patients with negative expression of breast cancer susceptibility gene 1/2 protein.